BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Tyrosine Pharma Names Seasoned Industry Exec Laslie President And CEO


12/5/2013 6:18:16 AM

Tyrosine appointed a new CEO but others are hiring for all kinds of positions too! Check it out! (Isn't it tempting?)

Tyrosine Pharma Names Seasoned Industry Exec Laslie President and CEO

ALBUQUERQUE, N.M., December 4, 2013 - - Tyrosine Pharma, Inc., has announced the appointment of Wayne Laslie as president and chief executive officer. Tyrosine Pharma is a New Mexico-based biotech company that is developing a treatment for stroke based on a derivative of a human protein. Tyrosine Pharma has licensed patented technology for the STEP peptide from STC.UNM created at the University of New Mexico to develop a novel treatment for ischemic stroke.

Laslie has more than 30 years of experience in pharmaceutical commercialization. He is the former chief operating officer and chief commercialization officer for Myrexis and Myriad Pharmaceuticals, drug development companies headquartered in Salt Lake City, Utah. Previously, he was head of the commercial group at Otsuka America Pharmaceuticals, where he oversaw the launch of new drugs, including Pletal and Abilify. Prior to Otsuka, Laslie held senior commercial positions in Europe and the United States with the predecessor companies of Sanofi as well as clinical and marketing positions with Pfizer.

Laslie joins a strong leadership team at Tyrosine Pharma that includes chief financial officer Alan Kolod, former chief financial officer of Future Medical Systems Group. The inventor of the technology is Dr. Surojit Paul, associate professor of Neurosciences at the University of New Mexico.

Current treatment options for blood clot-induced ischemic stroke—which account for 87 percent of strokes—are limited and little used. Tyrosine is developing a post-stroke injection designed to protect patients from brain injury by arresting the progression of brain damage caused by reduced blood flow. The goal is to reduce deaths, long-term disability and the financial impact of stroke.

The need for effective stroke therapies is great. Stroke is a leading cause of death in the United States, claiming 130,000 lives each year. The financial impact of stroke is also significant; in 2010 alone, the cost of health care, medications, and missed work to the U.S. economy was $73.7 billion. Stroke is also the leading cause of long-term disability. African-Americans, Hispanics, and Native Americans are disproportionately affected by stroke.

About Tyrosine Pharma, Inc.

Tyrosine Pharma, Inc., is a New Mexico-based biotech start-up company and a New Mexico Angels Technology Showcase Company. Visit www.tyrosinepharma.com for additional information.

For More Information

Melanie Lux, 803-331-4794 mlux@luxandassociates.com

Don't forget, hundreds of biopharma companies are hiring! (We know you can't resist.)


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES